Head-to-head comparison
| Property | Orforglipron | Tirzepatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Research Only | Prescription |
| Primary Route | oral | subcutaneous |
| Half-life | 25-68 hours (single dose: 24.6-35.3h; steady state: 48.1-67.5h); supports once-daily dosing | ~5 days |
| Mol. Weight | 882.97 Da | 4,813.45 Da |
| Side Effects | Nausea, Vomiting, Diarrhea | Nausea (up to 31%), Diarrhea, Vomiting |
Key differences
- Route: Orforglipron is an oral pill taken once daily with no food or water restrictions; tirzepatide is a once-weekly subcutaneous injection.
- Mechanism: Orforglipron is a GLP-1-only agonist that binds via a non-peptide transmembrane domain interaction; tirzepatide is a dual GIP/GLP-1 agonist that activates both incretin receptors for synergistic metabolic effects.
- Efficacy: Tirzepatide produced 22.5% mean weight loss at 15 mg over 72 weeks in SURMOUNT-1; orforglipron achieved 12.4% mean weight loss at 36 mg over 72 weeks in ATTAIN-1.
- Molecule type: Orforglipron is a small molecule (MW ~883 Da) with oral bioavailability of 30-40%; tirzepatide is a peptide (MW ~4,813 Da) requiring injection.
- Dosing convenience: Orforglipron eliminates injection burden entirely and has no meal-timing restrictions; tirzepatide requires weekly self-injection but only once per week versus daily oral dosing.
- Legal status: Tirzepatide is FDA-approved as Mounjaro (T2D) and Zepbound (obesity); orforglipron has completed Phase 3 trials with regulatory submissions filed but is not yet approved as of April 2026.
- Side effects: Both share GLP-1-class GI effects (nausea, vomiting, diarrhea). Orforglipron additionally reports dyspepsia related to oral delivery; tirzepatide causes injection site reactions.
The verdict
Tirzepatide delivers substantially greater weight loss than orforglipron, consistent with its dual GIP/GLP-1 mechanism versus GLP-1-only activation. Orforglipron's primary advantage is oral administration without injection burden, making it potentially better suited for patients who refuse or cannot tolerate injections. The ATTAIN-MAINTAIN trial showed orforglipron can maintain weight loss in patients transitioning from injectable incretins, suggesting a possible role as an oral maintenance therapy after injectable induction.
Frequently asked questions
No. Tirzepatide produced 22.5% mean weight loss in SURMOUNT-1, while orforglipron achieved 12.4% in ATTAIN-1 over similar timeframes. The difference is consistent with tirzepatide's dual GIP/GLP-1 mechanism providing greater metabolic effects than GLP-1-only activation.
The ATTAIN-MAINTAIN trial showed orforglipron can maintain weight loss in patients switching from injectable incretins including tirzepatide. This suggests a potential role as an oral maintenance option, though with lower peak efficacy than continued injectable tirzepatide therapy.
No. Orforglipron and tirzepatide are different molecules from different chemical classes. Orforglipron is a non-peptide small molecule that activates only GLP-1 receptors. Tirzepatide is a peptide that activates both GIP and GLP-1 receptors. Both are developed by Eli Lilly but serve different roles in the incretin therapy landscape.
The primary reason is avoiding injections. Orforglipron is an oral daily pill with no food or water restrictions, eliminating needle burden entirely. Some patients refuse injectable therapy, and orforglipron offers a GLP-1-pathway option for those individuals despite lower peak efficacy.
No. As of April 2026, orforglipron is an investigational drug with Phase 3 trials complete and global regulatory submissions filed. Eli Lilly expects US regulatory action for obesity in Q2 2026. Tirzepatide is already FDA-approved as Mounjaro for diabetes and Zepbound for obesity.